Orbimed Advisors LLC

Orbimed Advisors LLC (10% owner) sold 860,123 shares for $39,014,045.60 at blended average $45.36

Orbimed Advisors LLC executed 4 separate sales totaling 860,123 shares for $39,014,045.60 on 2026-06-22, reducing its stake from 7,415,225 shares to 6,555,102 shares (an 11.6% reduction in holdings). The blended average sale price of $45.36 occurred when the stock was trading at $47.77 current price, positioning 4.4% below the 52-week high of $49.94. Across Orbimed's cross-ticker track record, prior sells averaged 30-day return of -8.3% and 90-day return of -17.2%, with a 90-day well-timed rate of 100.00%, indicating a strong historical pattern of selling before declines. The company remains unprofitable with net income of -$23,627,000.00 over its most recent full fiscal year, which provides material context for a large institutional holder's decision to reduce exposure at this scale.

Orbimed Advisors (10% owner) sells 281.4K shares at $45.02 for $12.7M; retains 7.39M shares. Stock up 49.3% in 90 days.

Orbimed Advisors, a 10% shareholder, executed 2 separate sales totaling 281,408 shares for $12,668,988.16 on 2026-06-15 at $45.02 per share, reducing its stake by 3.7% to 7,388,902 shares remaining. This represents a material but non-controlling reduction in a major holder's position while the company remains unprofitable with net income of $-23,627,000.00 for its most recent full fiscal year. Across Orbimed's cross-ticker track record, the insider's prior 15 sales showed an average 90-day return of -17.2% with a 100.00% well-timed rate, indicating a pattern of selling before downturns; however, ELVN has appreciated 49.3% over the prior 90 days and 13.2% over the past 30 days, trading within 7.6% of its 52-week high of $48.53. The sale occurs amid strong near-term price momentum in an unprofitable biotech, warranting investor attention to whether this reflects external capital needs or a divergence from Orbimed's typical well-timed exit pattern.

Orbimed Advisors LLC (Director) purchases 1,875,000 shares for $15,000,000.00 in private placement at Q32 Bio.

Orbimed Advisors LLC purchased 1,875,000 shares across 2 separate transactions on 2026-05-28, paying $8.00 per share for a total of $15,000,000.00. However, this transaction is flagged as a private placement—not a discretionary open-market purchase—and therefore should not be interpreted as an expression of insider conviction about the stock's near-term prospects. The stock currently trades at $11.66, up 131.4% over 30 days and 138.4% over 90 days, placing it 11.3% below its 52-week high of $13.15. Q32 Bio is an early-stage biotech company with zero quarterly revenue and a net loss of $7,609,000.00, typical for pre-commercial stage enterprises. The private-placement structure indicates this was a structured financing event rather than an open-market vote of confidence, limiting the signal value for momentum or directional conviction.

Director Orbimed Advisors Llc sells ~293k shares (~$13.4M) over three days as stock trades near its 52-week high.

Orbimed Advisors, a director at Sionna Therapeutics, disposed of roughly 293,000 shares across three trading days in early May, representing approximately 10% of their total holding and netting over $13 million. The timing is notable: the stock has rallied significantly over the prior quarter and trades near its 52-week high, a position where insiders often choose to lighten exposure. However, this director's own historical record at this company shows mixed timing on prior sales—about half of their previous exits saw the stock rise afterward (poorly timed exits), while the other half preceded stock declines (well-timed exits). The company itself remains unprofitable with substantial net losses and negative earnings, so this sale comes against the backdrop of fundamental weakness. Orbimed's filing history shows a clear pattern: 144 prior open-market sales across all holdings over the 36-month window, with this transaction representing the 145th-147th sale. The volume and frequency of sales relative to zero open-market purchases in the same period suggests this is a holder managing a large position, not an insider with accumulated operational conviction in the company.

OrbiMed Advisors acquires 597,729 shares of Traws Pharma at $1.67 as losses widen; stock down 61.3% YTD

OrbiMed Advisors, a 10% shareholder, purchased 597,729 shares at $1.67 on 2026-04-16, nearly doubling its stake from 605,521 to 1,203,250 shares. The transaction occurred amid a sharp deterioration: Traws reported a net loss of $-3.0M against revenue of $2.7M, and the stock has declined 61.3% from its 52-week high of $3.13. Notably, OrbiMed's cross-ticker buy track record shows 6 prior purchases with an average 90-day return of +360.7% and a 100% win rate, though this represents historical performance across multiple holdings, not predictive evidence of outcomes at Traws specifically. The purchase price of $1.67 now trades 27% below the transaction price at a current price of $1.21, reflecting continued negative momentum (30-day decline of -31.2%) since the acquisition.

ORBIMED ADVISORS LLC (Director) purchased 2,815,315 shares for $12,499,998.60 at $4.44 on 2026-04-21

ORBIMED ADVISORS LLC, a Director, executed 2 separate purchases totaling 2,815,315 shares (2.82M shares) for $12,499,998.60 ($12.5M) at a blended average price of $4.44 on 2026-04-21. The transaction represents a substantial commitment: post-transaction holdings of 1,126,126 shares reflect a net increase from a pre-transaction position of -1,689,189 shares. The stock is currently trading at $4.40, only -20.3% from its 52-week high of $5.52 and up +41.0% over 30 days and +117.8% over 90 days. ORBIMED's cross-ticker track record shows strong performance on buys (5 prior buys with 100% 90-day win rate and +469.9% average 30-day return) against a more mixed record on sells (75% well-timed rate). Prelude Therapeutics remains unprofitable with quarterly revenue of $6,500,000 ($6.5M) and net income of $-19,725,000 ($-19.7M), though the company posted +73.4% annual revenue growth. The large capital commitment by a director at current valuations into an unprofitable but high-growth biotech company should be monitored against the company's path to profitability and execution on its pipeline.

Director-level ORBIMED ADVISORS sold 55,345 shares ($2.5M) at $44.67–$44.68 over 2 days; stock now $41.79, post-sale 2.96M shares held (unprofitable company, $-20.3M net income)

ORBIMED ADVISORS LLC executed 2 separate sales totaling 55,345 shares for $2,472,342.92 on 2026-04-17 and 2026-04-18, reducing holdings by 1.8% to 2,964,774 shares. The company remains unprofitable with net income of $-20,278,000.00 on a $1.9B market cap. The insider sold at a blended average price of $44.67, currently 6.9% above the current price of $41.79. Prior trades at SION show 5 prior sells; the 2 most recent (2026-02-02 and 2026-02-03) both posted negative 30-day returns (-22.4% and -22.5% respectively), suggesting potential timing alignment with subsequent declines, though 90-day outcomes remain unmeasurable. The cross-ticker track record shows a 75.00% well-timed rate on 13 prior sells with an average 90-day return of -11.8%, indicating a pattern of sells positioned ahead of downside—a signal that may warrant investor attention given the company's ongoing unprofitability.

OrbiMed Advisors sells 510,583 shares (14.5% of holdings) over 3 days for $22.9M at prices near 52-week high.

OrbiMed Advisors, a director of Sionna Therapeutics, executed 3 separate sales totaling 510,583 shares for $22,945,043.50 at a blended average price of $44.94 on April 14–16, 2026, reducing holdings from 3.53M to 3.02M shares (−14.5%). The transaction occurred near the stock's 52-week high of $45.24, which the shares have not exceeded. At the ticker level, OrbiMed's prior 3 measurable sells at SION all yielded negative 90-day returns (−4.9%, −22.0%, −16.1%, −19.1%), with 3 of 3 well-timed at the 90-day mark; the two most recent sales in early February show −22.5% and −22.4% 30-day declines. Against this backdrop, a substantial reduction in holdings at peak valuations follows a pattern of selling into strength at this specific ticker. The company remains unprofitable with net income of −$20.3M for its most recent full fiscal year.

Director ORBiMed Advisors LLC sold 30,953 shares at $44.57–$44.58 for $1,379,865.84; retains 3,530,702 shares

ORBiMed Advisors LLC, a director at Sionna Therapeutics, executed 2 separate sales totaling 30,953 shares for $1,379,865.84 on February 2–3, 2026, reducing holdings from 3,561,655 to 3,530,702 shares (a -0.9% reduction). The stock is now trading at $41.32, down 7.1% from the 52-week high of $44.48, while the broader 90-day trend shows +20.1% appreciation. ORBiMed's prior sales at SION have not exhibited well-timed 90-day outcomes (0 of 4 measurable), and his cross-ticker sell history shows a 66.67% well-timed rate; the company's net income of $-20,278,000.00 and 3.53M-share post-transaction holdings reflect its pre-revenue/early-stage biotech profile. This sale occurs near the stock's 52-week highs and follows a cluster of four sales in late November–December 2025, warranting tracking of whether this reflects a broader position reduction at this holder level.

Director ORBIMED ADVISORS LLC sold 33,356 shares of SION at $44.55 on 2025-12-24, reducing holdings from 3.60M to 3.56M shares.

ORBIMED ADVISORS LLC sold 33,356 shares (33.4K shares) at $44.55, representing a 0.9% reduction from pre-transaction holdings of 3,595,011 shares (3.60M shares). The sale occurred at a price near the 52-week high of $44.38, within 3.5% of peak valuations despite a current price of $42.81. Contextually, the insider's cross-ticker track record shows a 70.00% well-timed sell rate across 14 prior open-market sales (higher returns after the sale indicate poor timing; negative 90d average of +0.7% suggests marginal execution), though this same-ticker history at SION is nascent—three prior consecutive sales on 2025-11-24, 2025-11-25, and 2025-11-26 each showed modest declines over 30 days but lack measurable 90-day outcomes. The company faces structural headwinds: net income of $-20,278,000.00 ($-20.3M) paired with a $1.9B market cap signals an early-stage biotech without near-term profitability.